Third Harmonic Bio
Third Harmonic Bio is a biopharmaceutical company focused on driving the next wave of drugs for inflammatory diseases through the development of novel, highly selective small molecule inhibitors of KIT, a cell surface receptor that acts as the master regulator of mast cell function and survival.
Preliminary clinical studies demonstrate that KIT inhibition has the potential to revolutionize the treatment of a wide range of mast cell-mediated inflammatory diseases, and that an oral, titratable intracellular small molecule inhibitor could offer the optimal therapeutic profile against this target.
Third Harmonic Bio's lead product candidate, THB335, is a titratable, oral, intracellular small molecule inhibitor scheduled to enter clinical trials in the first half of 2024.